666 THIRD AVENUE, 9TH FLOOR,
NEW YORK , NY, 10017
NEW YORK , NY, 10017
Summary
The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.
The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.
As part of its strategy, the fund employs a passive or indexing investm More
Webiste
Directors
Dec 13, 2023- Laurie A. Hesslein
- R. Alastair Short
- Richard D. Stamberger
- Peter J. Sidebottom
- David H. Chow
- Jan F. Van Eck
Chief Compliance Officer
- Francesco Michael Gozzillo
Price
- $ 71.76 ( -5.75 )
-
Apr 10, 2025Last Close
- Net Assets
-
$450.6M
Feb 22, 2024
- 52-Week High/Low
- $90.3 - $71.8
- Expense Ratio
- -
Performance
YTD
0%
3 Year
-14.53%
5 Year
25%
Best
36.68%
2013
Worst
-23.34%
2002
Company Name |
Holding |
| Eli Lilly & Co | 13.28 % |
| Novo Nordisk A/S | 10.13 % |
| Johnson & Johnson | 5.97 % |
| Merck & Co Inc | 5.67 % |
| State Street Global Advisors | 5.65 % |
| AbbVie Inc | 5.54 % |
| Novartis AG | 5.06 % |
| AstraZeneca PLC | 4.89 % |
| Pfizer Inc | 4.57 % |
| Sanofi SA | 4.52 % |
| More | 4.52 % |
Documents
NAV
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PPH | 0% | 2.4% | 4.7% | 1.9% | 16.8% | 1.9% | 17% | -5.9% | 15.2% | -17.8% | |
| S&P 500 | -10.2% | 23.3% | 24.2% | -19.4% | 27.3% | 16.2% | 28.9% | -6.2% | 19.4% | 9.5% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| q1 | 0% | 3.3% | -0.1% | 4.6% | 3.8% | -15.2% | 10.1% | -4.2% | 5% | -12% | ||||
| q2 | 0% | -1.7% | 1.5% | -3.7% | 7.3% | 14.5% | -3.2% | 7.6% | 8% | 3.1% | ||||
| q3 | 0% | 0% | 1.4% | -12.5% | 0.1% | -1.8% | -3% | 9.2% | -1.7% | -1.5% | ||||
| q4 | 0% | 0% | 2.8% | 15.6% | 5.7% | 6.9% | 12.4% | -14.2% | 1.9% | -8% |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2024 | -3% | 4.1% | 2.4% | -2.4% | 1.6% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |